Connect with us


New STRENGTH analysis puts spotlight on CV impact of omega-3 fatty acids – Healio

Higher blood levels of eicosapentaenoic acid 1 year after daily omega-3 carboxylic acid supplementation were not associated with lower CV risk, according to a secondary…



Source: Nissen SE, et al. Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).
AstraZeneca funded the STRENGTH trial. Nissen reports he has received institutional research grants from AbbVie, Amgen, AstraZeneca, Eli Lilly, Esperion, Ethicon Endosurgery, Medtronic, Novartis, Orexigen, Pfizer, Resverlogix, Takeda…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
Coronavirus Update: Pfizer over Moderna? Some Canadians are vaccine shopping for no reason – The Globe and Mail
Article feature image
Science moves closer to broken heart cure – The West Australian